Trial reportIndian journal of pediatrics2021
Nebulized Magnesium Sulphate in Bronchiolitis: A Randomized Controlled Trial.
Trial report in Indian journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Nebulised Magnesium Sulphate Plus Epinephrine versus Epinephrine Alone in Infants with Acute Bronchiolitis.Indian journal of pediatrics · 2025Article
- Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children.World journal of pediatrics : WJP · 2024Review
- Current Approaches in the Multimodal Management of Asthma in Adolescents-From Pharmacology to Personalized Therapy.Biomedicines · 2023Review
- Inhaled Magnesium in Acute Bronchiolitis: Another One Bites the Dust?Indian journal of pediatrics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of nebulized magnesium sulphate as a bronchodilator in young children aged 1-24 mo with moderate to severe bronchiolitis in comparison to standard therapy.
methodsThis was an open labeled randomized controlled trial comprising 60 children with moderate to severe bronchiolitis which was randomly assigned to 2 groups. Intervention group received nebulization with 3 mL of 3.2% magnesium sulphate (MgSO
resultsThe mean age of children allocated in the control group was 7.4 ± 5.1 mo and 7.7 ± 4.5 mo in the intervention group. There was no significant difference with respect to improvement of BSS or reduced length of hospitalization in both the groups (p > 0.05). BSS monitored sequentially after enrollment at 1, 2, 4, 8, 12, 16, and 24 h did not show statistically significant differences between the groups. Mean length of hospital stay was 2.89 ± 2.25 d in treatment group and 2.96 ± 1.86 d in control group (p = 0.902). No adverse events were observed in both the groups.
conclusionNebulized magnesium sulphate is not superior to standard therapy in children with moderate to severe bronchiolitis. CLINICAL TRIAL REGISTRATION NUMBER: CTRI/2018/06/014400.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.